0001193125-26-099339
SEC filingQ32 Bio Inc. reported a profitable fiscal year 2025 with net income of $29.8 million, driven primarily by collaboration arrangement revenue of $53.7 million and a significant gain on sale of asset of $11.7 million. The company generated income from operations of $16.9 million despite total operating expenses of $36.8 million, which included research and development costs of $19.2 million and general and administrative expenses of $17.7 million. The balance sheet shows total assets of $61.8 million, with cash and cash equivalents of $48.3 million and total stockholders' equity of $42.0 million. However, cash flow from operations was negative at -$33.5 million, primarily due to non-cash revenue recognition and working capital changes, resulting in a net decrease in cash of $29.7 million for the year. The company's basic and diluted earnings per share were both $2.00.
Q32 Bio Inc. reported strong financial results for fiscal year 2025 with net income of $29.8 million, representing a significant turnaround from prior periods. The company generated $53.7 million in collaboration arrangement revenue and achieved income from operations of $16.9 million despite total operating expenses of $36.8 million. A notable gain on sale of asset of $11.7 million contributed to total other income of $12.9 million. The company reported basic and diluted earnings per share of $2.00 based on weighted-average common shares of 12.3 million. These results demonstrate improved operational performance compared to historical periods, though cash flow metrics present a different picture with negative operating cash flow.
The company's revenue for fiscal year 2025 consisted entirely of collaboration arrangement revenue totaling $53.7 million. No segment breakdown or geographic revenue mix was disclosed in the provided data. The revenue appears to be primarily driven by collaborative arrangements rather than product sales or other revenue streams. The document does not provide specific information about revenue growth drivers, customer concentration, or contract details. The absence of segment data suggests the company operates as a single reporting segment focused on its biopharmaceutical development activities.
Q32 Bio achieved an operating margin of 31.5% based on operating income of $16.9 million and revenue of $53.7 million. The company's cost structure included research and development expenses of $19.2 million (35.8% of revenue) and general and administrative expenses of $17.7 million (33.0% of revenue). No gross profit or gross margin information was disclosed in the provided data, suggesting the company may not have traditional cost of goods sold. The net income margin was 55.5%, significantly higher than the operating margin due to the substantial gain on sale of asset and other income items.
The company reported negative operating cash flow of -$33.5 million despite net income of $29.8 million, primarily due to non-cash revenue recognition of $53.7 million from settlement of customer refund liability and working capital changes. Investing activities provided $7.0 million from asset sales, while financing activities used $3.1 million for debt repayments. The balance sheet shows total assets of $61.8 million, with current assets of $55.0 million including cash and cash equivalents of $48.3 million. Total liabilities were $19.8 million, including venture debt of $9.7 million. Stockholders' equity stood at $42.0 million with accumulated deficit of -$205.0 million.
The provided data does not include specific forward-looking statements, management guidance, or strategic priorities for future periods. No information about upcoming clinical trials, pipeline developments, or regulatory milestones was included in the financial data sections. The company's cash position of $31.3 million at year-end, combined with negative operating cash flow, suggests potential liquidity considerations for future operations. Risk factors and future plans would typically be detailed in the Management's Discussion and Analysis section, which was not provided in the input data.